Does the media refer more to INDV or AVLN?

In the previous week, Avalyn Pharma had 4 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Avalyn Pharma and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Avalyn Pharma's score of 0.24 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AVLN or OGN?

In the previous week, Avalyn Pharma had 6 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Avalyn Pharma and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.32 beat Avalyn Pharma's score of 0.24 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TARS or AVLN?

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 8 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Avalyn Pharma's score of 0.24 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARQT or AVLN?

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Avalyn Pharma. MarketBeat recorded 12 mentions for Arcutis Biotherapeutics and 8 mentions for Avalyn Pharma. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Avalyn Pharma's score of 0.24 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RGC or AVLN?

Avalyn Pharma has a consensus target price of $60.00, indicating a potential upside of 132.92%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalyn Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has better valuation & earnings, RGC or AVLN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Avalyn Pharma N/A N/A N/A -$22.81 N/A

Is RGC or AVLN more profitable?

Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Avalyn Pharma N/A N/A N/A

Does the media refer more to RGC or AVLN?

In the previous week, Avalyn Pharma had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Avalyn Pharma and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.33 beat Avalyn Pharma's score of 0.24 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Avalyn Pharma (AVLN) Competitors

$25.76 +0.04 (+0.16%)

As of 10/9/2026 04:00 PM Eastern

Compare

AVLN vs. INDV, OGN, TARS, ARQT, and RGC

Should you buy Avalyn Pharma stock or one of its competitors? Avalyn Pharma's main competitors and comparable companies include Indivior (INDV), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), and Regencell Bioscience (RGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avalyn Pharma compare to Indivior?

Indivior (NASDAQ:INDV) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Indivior presently has a consensus target price of $45.17, indicating a potential upside of 26.06%. Avalyn Pharma has a consensus target price of $60.00, indicating a potential upside of 132.92%. Given Avalyn Pharma's higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Indivior has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.33B	3.18	$210M	$2.79	12.84
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

Indivior has a net margin of 26.65% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Avalyn Pharma	N/A	N/A	N/A

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Avalyn Pharma had 4 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Avalyn Pharma and 4 mentions for Indivior. Indivior's average media sentiment score of 1.40 beat Avalyn Pharma's score of 0.24 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Indivior beats Avalyn Pharma on 10 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Organon & Co.?

Avalyn Pharma (NASDAQ:AVLN) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Organon & Co. has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.93

Organon & Co. has a net margin of 3.41% compared to Avalyn Pharma's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Organon & Co.	3.41%	88.97%	6.03%

In the previous week, Avalyn Pharma had 6 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Avalyn Pharma and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.32 beat Avalyn Pharma's score of 0.24 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avalyn Pharma currently has a consensus target price of $60.00, indicating a potential upside of 132.92%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 17.42%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Avalyn Pharma is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Organon & Co. beats Avalyn Pharma on 9 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Avalyn Pharma has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.11	-$66.42M	-$1.09	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 8 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Avalyn Pharma's score of 0.24 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals presently has a consensus price target of $100.86, indicating a potential upside of 37.86%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 132.92%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Avalyn Pharma has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Avalyn Pharma's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Tarsus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Avalyn Pharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Arcutis Biotherapeutics currently has a consensus price target of $36.00, indicating a potential upside of 35.44%. Avalyn Pharma has a consensus price target of $60.00, indicating a potential upside of 132.92%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Avalyn Pharma. MarketBeat recorded 12 mentions for Arcutis Biotherapeutics and 8 mentions for Avalyn Pharma. Arcutis Biotherapeutics' average media sentiment score of 0.49 beat Avalyn Pharma's score of 0.24 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a net margin of 6.15% compared to Avalyn Pharma's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has lower revenue, but higher earnings than Arcutis Biotherapeutics. Avalyn Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.88	-$16.14M	$0.21	126.57
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

Summary

Arcutis Biotherapeutics beats Avalyn Pharma on 9 of the 12 factors compared between the two stocks.

How does Avalyn Pharma compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

In the previous week, Avalyn Pharma had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 8 mentions for Avalyn Pharma and 3 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.33 beat Avalyn Pharma's score of 0.24 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A

Avalyn Pharma has a consensus target price of $60.00, indicating a potential upside of 132.92%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Avalyn Pharma beats Regencell Bioscience on 5 of the 8 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-1.13	797.58	274.15	26.16
Price / Sales	N/A	757.89	590.50	94.68
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	N/A	10.71	11.21	6.34
Net Income	N/A	$2.84B	$3.50B	$381.90M
7 Day Performance	-8.43%	-0.93%	-0.90%	-1.41%
1 Month Performance	-25.70%	-4.91%	-4.44%	-3.48%
1 Year Performance	N/A	-4.13%	6.96%	1.16%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	2.8468 of 5 stars	$25.76 +0.2%	$60.00 +132.9%	N/A	$1.14B	N/A	N/A	55
INDV Indivior	4.5161 of 5 stars	$35.71 +0.9%	$45.17 +26.5%	+48.4%	$4.18B	$1.24B	12.80	838
OGN Organon & Co.	1.2227 of 5 stars	$13.74 +0.2%	$11.40 -17.0%	+39.3%	$3.60B	$6.22B	17.84	10,000	Analyst Upgrade
TARS Tarsus Pharmaceuticals	3.5604 of 5 stars	$73.00 -3.3%	$100.86 +38.2%	+3.9%	$3.31B	$451.36M	N/A	370	Analyst Downgrade
ARQT Arcutis Biotherapeutics	4.2032 of 5 stars	$25.16 -0.5%	$35.57 +41.4%	+28.3%	$3.18B	$376.07M	119.82	354	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. INDV, OGN, TARS, ARQT, and RGC

How does Avalyn Pharma compare to Indivior?

Summary

How does Avalyn Pharma compare to Organon & Co.?

Summary

How does Avalyn Pharma compare to Tarsus Pharmaceuticals?

Summary

How does Avalyn Pharma compare to Arcutis Biotherapeutics?

Summary

How does Avalyn Pharma compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. INDV, OGN, TARS, ARQT, and RGC

How does Avalyn Pharma compare to Indivior?

Do analysts recommend INDV or AVLN?

Which has higher earnings and valuation, INDV or AVLN?

Is INDV or AVLN more profitable?

Do insiders & institutionals have more ownership in INDV or AVLN?

Does the media refer more to INDV or AVLN?

Summary

How does Avalyn Pharma compare to Organon & Co.?

Which has higher valuation & earnings, AVLN or OGN?

Is AVLN or OGN more profitable?

Does the media favor AVLN or OGN?

Do insiders and institutionals have more ownership in AVLN or OGN?

Do analysts rate AVLN or OGN?

Summary

How does Avalyn Pharma compare to Tarsus Pharmaceuticals?

Which has higher valuation & earnings, TARS or AVLN?

Do insiders & institutionals believe in TARS or AVLN?

Does the media refer more to TARS or AVLN?

Do analysts rate TARS or AVLN?

Is TARS or AVLN more profitable?

Summary

How does Avalyn Pharma compare to Arcutis Biotherapeutics?

Do analysts recommend ARQT or AVLN?

Does the media favor ARQT or AVLN?

Is ARQT or AVLN more profitable?

Which has stronger earnings & valuation, ARQT or AVLN?

Summary

How does Avalyn Pharma compare to Regencell Bioscience?

Which has better valuation & earnings, RGC or AVLN?

Does the media refer more to RGC or AVLN?

Is RGC or AVLN more profitable?

Do analysts recommend RGC or AVLN?

Do institutionals & insiders believe in RGC or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools